Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: A randomized, controlled trial

Alimentary Pharmacology and Therapeutics

Volumn 21, Issue 4, 2005, Pages 435-444

  Ducrotte, P ^a   Dapoigny, M ^b   Bonaz, B ^c   Siproudhis, L ^d  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM DERIVATIVE; BEIDELLITIC MONTMORILLONITE; LAXATIVE; MACROGOL; MAGNESIUM SILICATE; MONTMORILLONITE; PHLOROGLUCINOL; PLACEBO; SPASMOLYTIC AGENT; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ANGINA PECTORIS; ARTICLE; BACKACHE; BRONCHITIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ENDOMETRIOSIS; EPIGASTRIC PAIN; FEMALE; HEADACHE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; PHARYNGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; TREATMENT OUTCOME;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALUMINUM SILICATES; BENTONITE; CONSTIPATION; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 14644444173     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02330.x     Document Type: Article

References (21)

1. Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997; 112: 2120-37.
2. Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001; 48: 272-82.
3. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000; 133: 136-47.
4. Talley NJ. Pharmacologic therapy for the irritable bowel syndrome. Am J Gastroenterol 2003; 98: 750-8.
5. Hahn BA, Kirchdoerfer LJ, Fullerton S, Mayer EA. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther 1997; 11: 553-9.
6. Leong S, Barghout V, Birnbaum H, et al. The economic consequences of irritable bowel syndrome: a US employer perspective. Arch Intern Med 2003; 163: 929-35.
7. Delvaux M. Functional bowel disorders and irritable bowel syndrome in Europe. Aliment Pharmacol Ther 2003: 18(Suppl.): 75-9.
8. Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia, Gastroenterology 1994; 107: 271-93.
9. Furness JB, Kunze WA, Clerc N. Nutrient tasting and signalling mechanisms in the gut. II. The intestine as a sensory organ: neural, endocrine and immune responses. Am J Physiol (Gastrointest. Liver Physiol.) 1999; 277: G922-8.
10. Serrano JJ. Bedelix: Critique du pouvoir couvrant intestinal et mesure de la surface spécifique. Med Chir Dig 1993; 22: 1-3.
11. Frexinos J, Lamarque F. Effet de la Montmorillonite beidellitique sur la concentration de l'hydrogène expiré. Am Gastroenterol Hépatol 1987; 23: 235-6.
12. Meknini B, Bernades P. Etude comparative de l'effet de Bedelix sur la surproduction de gaz intestinaux induite par un repas riche en hydrates de carbone fermentescibles. Med Chir Dig 1994; 23: 442-4.
13. Drossman DA, Richter JE, Talley NJ, et al.(eds) The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment. 1st edn. Mc Lean, VA, USA: Degnon Associates. 1994.
14. Perneger TV, Leplfge A, Elter JF, Rangemont A. Validation of a French language version of the MOS-36-Item Short form Health Survey (SF-36) in young healthy adults. J Clin Epidemiol 1995; 48: 1051-60.
15. Corazziari E, Bytzer P, Delvaux M, et al. Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18: 569-80.
16. Kamm MA. Entry criteria for drug trials in irritable bowel syndrome. Am J Med 1999; 107: S51-8.
17. Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355: 1035-40.
18. Camilleri M. Tegaserod, review article. Aliment Pharmacol Ther 2001; 15: 277-89.
19. Novick J, Miner P, Krause E, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877-88.
20. Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double-blind, placebo-controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52: 671-6.
21. Jones RH, Holtmann G, Rodrigo L, et al. Alosetron relieves pain and improve bowel function compared with mebeverine in female non-constipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13: 1419-27.